Cytek Biosciences, Inc.
Company Stats
- Market Cap
- $774.7M
- as of Sep 30, 2026
- Enterprise Value
- $684.4M
- Shares Outstanding
- 130.0M
- Free Float
- 89.5%
Income Statement
- Revenue
- $201.5M
- Operating Income
- -$40.4M
- Net Income
- -$66.5M
- EBITDA
- -$32.8M
- Revenue Growth, 3Y
- 7.1%
- FCF Margin, 3Y Avg
- 2.3%
- FCF Margin, Worst Year
- -4.4%
Cash Flow
- Free Cash Flow
- -$8.8M
- FCF Yield
- -1.1%
- Owner FCF Yield
- -4.3%
Balance Sheet
- Cash & Equivalents
- $90.9M
- Total Debt
- $525,000
- Net Cash
- $90.3M
Returns & Capital
- Share Repurchases
- $15.1M
- Buyback Yield, 3Y Avg
- 3.5%
- SBC, 3Y Avg
- $24.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $201.5M | -$8.8M | -4.4% |
| FY2024 | $200.5M | $21.9M | 10.9% |
| FY2023 | $193.0M | $633,000 | 0.3% |
| FY2022 | $164.0M | -$22.0M | -13.4% |
| FY2021 | $128.0M | $266,000 | 0.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 5, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Micro-Cap Earnings Roundup for Week of Nov. 2, 2026
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back